Stereotaxis and ADAS 3D Medical SL today announced the first patients have been successfully treated for cardiac arrhythmias through the combination of mapping and robotic precision technologies. The procedures were successfully conducted by Prof. Pedro Adragão of Hospital da Luz in Lisbon, Portgual.
The ADAS 3D technology helps identify possible sources of dangerous irregular heartbeats by providing a map to guide physicians in delivering treatment. The software uses preoperative cardiac MRI to generate 3D cardiac models that identify arrhythmia substrate and characterize cardiac tissue. Barcelona-based ADAS 3D said identifying fibrotic cardiac tissue and channels of electrical conduction is particularly valuable for planning Ventricular Tachycardia ablation procedures.
The latest version of Stereotaxis’ software, which has been cleared for use in Europe and the U.S., uses an interface that integrates the 3D images and allows physicians to use them to guide therapy during robotic cardiac ablation procedures.
“Life-threatening arrhythmias are common in patients that have suffered a myocardial infraction,” said Prof. Adragão. “Cardiac ablation can help these patients, but often require extensive searching to find targets and widespread ablation to ensure all problematic tissue has been addressed. ADAS 3D supports rapid and precise identification of such tissue. We have long recognized the clinical value of Robotic Magnetic Navigation to treat patients with precision and safety. The integration of both technologies should result in more effective, rapid, and safe procedures for patients.”
In addition to the Ventricular Tachycardia ablation procedures, the ADAS 3D software can be used during Atrial Fibrillation procedures to define the shape of the left atrium and its fibrosis distribution, quantifying it and improving guidance due to better identification of ablation targets, the company said.
“Stereotaxis is committed to advancing a robust open ecosystem where physicians and patients benefit from the broad integration of procedure data,” said David Fischel, CEO of St. Louis-based Stereotaxis. “We are excited to be working with ADAS 3D. The combination of advanced diagnostic imaging with robotic navigation is a step forward in the digitization of electrophysiology.”
In May, Stereotaxis introduced its Genesis RMN system, the latest version of its robotic magnetic navigation system. It is currently awaiting FDA approval. The original version of its system was commercialized in 2003, and consists of two robotically controlled magnets next to a table. During a procedure, a physician uses an intuitive computer interface to adjust the magnetic field around the patient, allowing the doctor to precisely direct and steer a catheter with a magnet embedded into its tip.
The new Genesis RMN system uses smaller magnets that rotate along their center of mass and are held by flexible robot arms. “This mechanism allows for instantaneous responsiveness to physician control, and the flexibility to accommodate an increased range of motion,” the company said in its Genesis RMN announcement.